SYNTHESIS OF SPACER-ARM, LIPID, AND ETHYL GLYCOSIDES OF THE TRISACCHARIDE PORTION [α -D-Gal-(1 \rightarrow 4)- β -D-Gal-(1 \rightarrow 4)- β -D-Glc] OF THE BLOOD-GROUP P^k ANTIGEN: PREPARATION OF NEO-GLYCOPROTEINS*

JAN DAHMÉN, TORBJORN FREJD[§], GORAN MAGNUSSON[§], GHAZI NOORI, AND ANNE-SOFIE CARLSTROM Swedish Sugar Co. Ltd., Research and Development, Box 6, S-232 00 Arlöv (Sweden) (Received June 14th, 1983; accepted for publication, September 22nd, 1983)

ABSTRACT

The title compounds were prepared via the acetylated 2-bromoethyl glycoside 11 of α -D-Gal-(1 \rightarrow 4)- β -D-Gal-(1 \rightarrow 4)- β -D-Glc by displacement of bromide ion with methyl 3-mercaptopropionate, octadecanethiol, and hydrogen, respectively. Silver triflate-promoted glycosylation of 2-bromoethyl 2,3,6-tri-O-benzyl- β -Dglucopyranoside with 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- α -D-galactopyranosyl bromide gave 11. A tetradeuterated analogue of 11 was prepared by essentially the same route. The spacer-arm glycoside formed from methyl 3-mercaptopropionate was coupled to bovine serum albumin and keyhole limpet haemocyanin.

INTRODUCTION

Globotriaosylceramide (the P^k-antigen²) and globotetraosylceramide (the Pantigen²) have been suggested to function as receptors for pathogenic *E. coli* bacteria in the human urinary tract³. Recently, globotriaosylceramide was identified as an antigen associated with the Burkitt lymphoma⁴. We recently reported an improved synthesis⁵ of the α -D-Gal-(1→4)-D-Gal unit (considered to be the important part of the *E. coli* receptor) of these ceramides, as well as a series of derivatives⁶⁻⁸ of value for the biological evaluation of the receptor phenomenon.

Methyl and p-nitrophenyl glycosides of the trisaccharide α -D-Gal-(1 \rightarrow 4)- β -D-Gal-(1 \rightarrow 4)-D-Glc of the P^k-antigen have been prepared⁹ via suitably protected lactose and galactose derivatives. We now report an alternative route, starting from 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- α -D-galactopyranosyl bromide (1) and 2-bromoethyl 2,3,6-tri-O-benzyl- β -D-glucopyranoside (6), leading to the 2-bromoethyl glycoside 11 that was used for the preparation of spacer-arm, lipid, and ethyl glycosides of the P^k-antigen.

^{*2-}Bromoethyl Glycosides, Part 5. For Part 4, see ref. 1.

⁸Present address: Organic Chemistry 2, Chemical Center, The Lund Institute of Technology, Box 740, S-220 07 Lund, Sweden.



Specifically deuterated derivatives of carbohydrates can be used to simplify interpretations of mass and ¹H-n.m.r. spectra, and as labelled compounds for biochemical and biological studies. A tetradeuterated analogue (26) of 11 has also been prepared.

RESULTS AND DISCUSSION

2-Bromoethyl 2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside⁷ (2) was deacetyl-

ated with methanolic sodium methoxide, and a solution of the product in N,N-dimethylformamide was immediately added to a mixture of zinc chloride and benzaldehyde¹⁰ to give 73% of the 4,6-O-benzylidene derivative **3**. Treatment of **3** with benzyl bromide, under conditions of phase-transfer catalysis, gave crystalline 2bromoethyl 2,3-di-O-benzyl-4,6-O-benzylidene- β -D-glucopyranoside (**4**) and 3-Obenzyl-4,6-O-benzylidene-1,2-O-ethylidene- β -D-glucopyranose (**5**), in yields of 80 and 20%, respectively. Treatment¹¹ of **4** with sodium cyanoborohydride gave 59% of 2-bromoethyl 2,3,6-tri-O-benzyl- β -D-glucopyranoside (**6**). Reaction of **3** with benzoyl chloride in pyridine gave 86% of the 2,3-dibenzoate **7**. Reduction of the benzylidene group in **7**, as described above¹¹, then gave 65% of 2-bromoethyl 2,3di-O-benzoyl-6-O-benzyl- β -D-glucopyranoside (**8**).

The partly protected 2-bromoethyl glycosides 6 and 8 were subjected to silver triflate-promoted glycosylations with 2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- α -D-galactopyranosyl bromide⁷ (1). With 6, 55% of the β -glycoside 9 was formed together with a small proportion of α -glycoside (see below), whereas, with 8, a ~3:1 $\alpha\beta$ -mixture (14 and 12) was obtained. Catalytic hydrogenolysis^{6,8} of 12 gave a quantitative yield of 13 which, on treatment with methanolic sodium methoxide and then reacetylation, gave the trisaccharide derivative 11.

Catalytic hydrogenation of 2-bromoethyl 2,3,6-tri-O-benzyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- β -D-galactopyranosyl]- β -D-glucopyranoside (9) in acetic acid (conditions under which the bromoethyl group does not react⁸) gave a quantitative yield of 10. Acetylation of 10 then gave 69% of the 2-bromoethyl glycoside 11. The tetradeuterated compound 26 was prepared by the same method from 23 and 6 via 24 and 25.

Nucleophilic displacement of bromide ion from 11, using methyl 3-mercaptopropionate¹² or octadecanethiol in *N*, *N*-dimethylformamide containing cesium carbonate, gave the spacer-arm glycoside 15 (87%) and the neoglycolipid 17 (87%). Deacetylation of 15 and 17 gave 2-(2-methoxycarbonylethylthio)ethyl 4-*O*-(4-*O*- α -D-galactopyranosyl- β -D-galactopyranosyl)- β -D-glucopyranoside (16, 97%) and 2-(octadecylthio)ethyl 4-*O*-(4-*O*- α -D-galactopyranosyl- β -D-galactopyranosyl)- β -D-glucopyranoside (18, 88%). The glycoside 16 was coupled to bovine serum albumin and keyhole limpet haemocyanin, using a modification¹ of the Inman-Lemieux procedure^{6,13,14} with methyl sulfoxide as solvent instead of *N*, *N*-dimethylformamide, thus furnishing the glycoproteins 21 and 22, respectively.

Catalytic hydrogenation of 11 under basic conditions⁶, with acetylation of the product, gave 62% of the ethyl glycoside 19. Deacetylation of 19 gave a quantitative yield of ethyl 4-O-(4-O- α -D-galactopyranosyl- β -D-galactopyranosyl)- β -D-glucopyranoside (20). The use of crude 11 in the latter reaction sequence gave a small proportion (<5%) of the α -glycoside (t.l.c. and ¹H-n.m.r.) that had been formed in the reaction of 6 with 1. The structure of 20 was confirmed by sugar¹⁵ and methylation¹⁶ analysis.

EXPERIMENTAL

General methods were as reported⁸. Me₄Si and sodium 3-(trimethyl-silyl)propionate- d_4 (TSP) were used as n.m.r. references.

2-Bromoethyl 4,6-O-benzylidene- β -D-glucopyranoside (3). — A solution of 2-bromoethyl 2,3,4,6-tetra-O-acetyl- β -D-glucopyranoside⁷ (2; 30 g, 66 mmol) in warm methanol (300 mL) was rapidly cooled and treated with methanolic 0.1M sodium methoxide (30 mL) at room temperature for 3 h. The reaction was monitored by t.l.c. (SiO₂; chloroform-methanol-water, 65:35:10, lower phase). The reaction mixture was filtered through a column (5 \times 4 cm) of Duolite C-26 (H⁺) resin and the solvent was removed. A solution of the residue (18.6 g) in N_1N_2 -dimethylformamide (20 mL) was added dropwise (10 min) with stirring to a mixture of zinc chloride (44 g, 103 mmol) and benzaldehyde (48 g, 471 mmol). After 21 h, ether (500 mL) and ice-water (300 mL) were added and the aqueous phase was extracted with ether $(2 \times 100 \text{ mL})$. The combined extracts were washed with aqueous sodium hydrogencarbonate $(2 \times 100 \text{ mL})$ and water (50 mL). Dichloromethane was added to prevent crystallisation. The solution was dried (Na₂SO₄) and concentrated, and the residue (18.1 g, 73%) was recrystallised from ethanol to give 3, m.p. 157–159°, $[\alpha]_{D}^{21}$ –43° (c 2, chloroform). N.m.r. data: ¹H (CDCl₃ + D₂O, Me₄Si), δ 5.52 (s, 1 H, PhCH), 4.43 (d, 1 H, J 8 Hz, H-1), 4.32 (dd, 1 H, J 11 and 5 Hz), and 4.14 (td, 1 H, J 6 and 11 Hz); 13 C (CDCl₃, Me₄Si), δ 103.3, 101.9 (C-1), and 30.1 (CH₂Br)

Anal. Calc. for C₁₅H₁₉BrO₆: C, 48.01; H, 5.10. Found: C, 48.18; H, 5.04.

2-Bromoethyl 2,3-di-O-benzyl-4,6-O-benzylidene- β -D-glucopyranoside (4) and 3-O-benzyl-4,6-O-benzylidene-1,2-O-ethylidene- β -D-glucopyranose (5). — A mixture of 3 (4.4 g, 11.7 mmol), benzyl bromide (20 mL, 77 mmol), tetrabutylammonium hydrogensulfate (0.5 g), and aqueous 10% sodium hydroxide (44 mL) was stirred at room temperature for 17 h, diluted with toluene, washed with water, dried (Na₂SO₄), and concentrated. Column (5 × 18 cm) chromatography (SiO₂; toluene, then 19:1 toluene-ethyl acetate, and finally ethyl acetate) gave 4 (5.2 g, 80%) and 5 (0.9 g, 20%).

Compound 4 had m.p. 97–98° (from ethanol), $[\alpha]_{21}^{21}$ –30° (*c* 2, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.58 (s, 1 H, PhC*H*), 4.98, 4.77 (ABq, 2 H, J_{AB} 11 Hz, PhC*H*₂), 4.92, 4.81 (ABq, 2 H, J_{AB} 11.5 Hz, PhC*H*₂), 4.56 (d, 1 H, *J* 7.5 Hz, H-1), 4.35 (dd, 1 H, *J* 10.5 and 5 Hz), 4.22 (dt, 1 H, *J* 11 and 5.5 Hz, C*H*₂CH₂Br), and 3.52 (bt, *J* 6 Hz, CH₂Br); ¹³C, δ 104.1, 101.1 (C-1), and 30.0 (CH₂Br).

Anal. Calc. for C₂₉H₃₁BrO₆: C, 62.70; H, 5.63. Found: C, 62.94; H, 5.62.

Compound **5** had m.p. 160.5–162.5° (from ethanol–ethyl acetate), $[\alpha]_D^{21} - 21^\circ$ (*c* 1.5, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.57 (s, 1 H, PhCH), 4.86 (s, 2 H, PhCH₂), 4.42 (d, 1 H, J 8 Hz, H-1), 4.38 (dd, 1 H, J 10 and 4.5 Hz), and 3.31 (bt, 1 H, J7.5 Hz); ¹³C, δ 101.5 and 99.1 (C-1 and PhCH).

Anal. Calc. for C₂₂H₂₄O₆: C, 68.73; H, 6.29. Found: C, 68.58; H, 6.33.

2-Bromoethyl 2,3,6-tri-O-benzyl-β-D-glucopyranoside (6). — A mixture of 4 (29.5 g, 53 mmol), sodium cyanoborohydride (9 g, 143 mmol), molecular sieves (3 Å, 30 g), and tetrahydrofuran (175 mL) was stirred while hydrogen chloride-saturated ether (225 mL) was added dropwise¹¹. Additional amounts of cyanoborohydride (1 g) and ethereal acid (25 mL) were then added. T.I.c. (SiO₂; toluene–ethyl acetate, 19:1) showed that **4** had been consumed. Toluene (500 mL) was added, and the mixture was washed with ice–water (250 mL) and cold aqueous sodium hydrogencarbonate (250 mL), dried (Na₂SO₄), and concentrated to give a semi-crystalline residue (32 g). Column (10 × 18 cm) chromatography (SiO₂; ethyl acetate–iso-octane, 1:2) and recrystallisation of the residue (17.5 g, 59%) from toluene–iso-octane gave **6**, m.p. 63–64°, $[\alpha]_D^{21} - 18°$ (*c* 1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.03, 4.72 (ABq, 2 H, J_{AB} 10.5 Hz, PhCH₂), 4.95, 4.72 (ABq, 2 H, J_{AB} 11.5 Hz, PhCH₂), 4.60, 4.57 (ABq, 2 H, J_{AB} 12.0 Hz, PhCH₂), 4.47 (d, with virtual coupling¹⁷, 1 H, J_{1.2} 7.5 Hz, H-1), and 4.23 (dt, 1 H, J 11 and 5.5 Hz, CH₂CH₂Br); ¹³C, δ 103.8 (C-1) and 30.3 (CH₂Br).

Anal. Calc. for C₂₉H₃₃BrO₆: C, 62.48; H, 5.97. Found: C, 62.64; H, 5.97.

2-Bromoethyl 2,3-di-O-benzoyl-4,6-O-benzylidene- β -D-glucopyranoside (7). — Benzoyl chloride (20 mL, 240 mmol) was added (7 min) dropwise with stirring to a solution at 0° of 3 (17 g, 45.3 mmol) in pyridine (85 mL). Ice-water (125 mL) was added after 1 h and the mixture was extracted with ether-dichloromethane (2:1, 750 mL). The extract was washed with aqueous sodium hydrogencarbonate (100 mL) and aqueous sodium chloride (100 mL), dried (Na₂SO₄), and concentrated. Recrystallisation of the residue (27.7 g, 82%) from toluene-ethanol gave 7, m.p. 176–178°, $[\alpha]_{D}^{21} - 0.1^{\circ}$ (c 1.1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.80 (t, 1 H, J 9 Hz, H-3), 5.55 (s, 1 H, PhCH), 5.50 (dd, 1 H, J 9 and 8 Hz, H-2), 4.88 (d, 1 H, J 8 Hz, H-1), 4.44 (dd, 1 H, J 10 and 5 Hz, H-5), 4.16 (dt, 1 H, J 11 and 6 Hz, CH₂CH₂Br), and 3.39 (t, 2 H, J 6 Hz, CH₂Br); ¹³C, δ 101.8 and 101.5 (C-1 and PhCH), and 29.5 (CH₂Br).

Anal. Calc. for C₂₉H₂₇BrO₈: C, 59.70; H, 4.66. Found: C, 60.08; H, 4.80.

2-Bromoethyl 2,3-di-O-benzoyl-6-O-benzyl- β -D-glucopyranoside (8). — A mixture of 7 (26.1 g, 45 mmol), sodium cyanoborohydride (7 g, 110 mmol), molecular sieves (4 Å, 20 g), and tetrahydrofuran (150 mL) was treated essentially as in the preparation of **6**, to give **8** (17.1 g, 65%). Recrystallisation from iso-octane-toluene gave material with m.p. 78–80°, $[\alpha]_D^{21}$ +53° (*c* 1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 4.76 (d with virtual coupling¹⁷, 1 H, $J_{1,2}$ 8 Hz, H-1), 4.65, 4.61 (ABq, 2 H, J_{AB} 12 Hz, PhCH₂), 4.14 (dt, 1 H, J 11 and 6 Hz, CH₂CH₂Br), and 3.40 (bt, 2 H, $J \sim 7$ Hz, CH₂Br); ¹³C, δ 101.1 (C-1) and 29.65 (CH₂Br).

Anal. Calc. for C₂₉H₂₉BrO₈: C, 59.49; H, 4.99. Found: C, 59.19; H, 5.11.

2-Bromoethyl 2,3,6-tri-O-benzyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- β -D-galactopyranosyl]- β -D-glucopyranoside (9). — A solution of 1^7 (21 g, 30 mmol) in dichloromethane (70 mL) was added (45 min) dropwise with stirring to a solution (-78° , N₂) of 6 (14 g, 25 mmol), silver tri-

fluoromethanesulfonate (9 g, 35 mmol), and tetramethylurea (4.6 g, 39.6 mmol) in dichloromethane (130 mL). After 5 h, the mixture, then at room temperature, was filtered through Celite, diluted with dichloromethane, washed with M hydrochloric acid and aqueous sodium hydrogenearbonate, dried (Na₂SO₄), and concentrated. The residue (35 g) was subjected to chromatography (SiO₂; ethyl acetate-iso-octane gradient, $1:1\rightarrow 3:2$) to give 1 (2 g) and 9 (16.5 g). Further chromatography of a fraction containing impure 9 gave additional material (1.3 g; total yield, 17.8 g, 70% based on reacted 6). Recrystallisation from ethanol gave material with m.p. 155–158°, $[\alpha]_{D}^{21}$ – 58° (c 1.2, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.58 (dd, 1 H, J 3 and <1 Hz, H-4"), 5.30 (dd, 1 H, J 11 and 3 Hz, H-3"), 5.17 (dd, 1 H, J 11 and 3.5 Hz, H-2"), 5.11 (dd, 1 H, J 11 and 8 Hz, H-2'), 5.03 (d, 1 H, J 11.5 Hz, PhCH₂), 4.94 (d, 1 H, J 3.5 Hz, H-1"), 4.94 (d, 1 H, J 11 Hz, PhCH₂), 4.83 (d, 1 H, J 11.5 Hz, PhCH₂), 4.74 (d, 1 H, J 12 Hz, PhCH₂), 4.69 (d, 1 H, J 11 Hz, PhCH₂), 4.67 (d. 1 H, J 8 Hz, H-1'), 4.58 (dd, 1 H, J 11 and 2.5 Hz, H-3'), 4.50 (d, 1 H, J 12 Hz, PhCH₂), 4.43 (d, 1 H, J 8 Hz, H-1), and 4.59-4.41 (3 H, inter alia H-1 and PhCH₂); ${}^{13}C$, δ 103.6 (d, J 158 Hz, C-1), 100.6 (d, J 156 Hz, C-1'), 99.8 (d, J 172 Hz, C-1"), and 30.2 (CH₂Br).

Anal. Calc. for C₅₅H₆₇BrO₂₃: C, 56.16; H, 5.74. Found: C, 55.90; H, 5.72.

2-Bromoethyl 4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-β-D-galactopyranosyl]-β-D-glucopyranoside (10). — Catalytic hydrogenation (1 atm., 10% Pd/C, 0.2 g) of 9 (1.05 g, 0.89 mmol) in acetic acid (50 mL) for 2 h, followed by filtration and removal of the solvent, gave 10 (0.81 g, 100%). Recrystallisation from methanol gave material with m.p. 178–180°, $[\alpha]_{D}^{21}$ +77° (c 1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.59 (bd, 1 H, J ~3 Hz, H-4″), 5.38 (dd, 1 H, J 11 and 3 Hz, H-3″), 5.24 (dd, 1 H, J 11 and 8 Hz, H-2′), 5.22 (dd, 1 H, J 11 and ~3 Hz, H-2″), 4.97 (d, 1 H, J 3.5 Hz, H-1″), 4.81 (dd, 1 H, J 11 and 3.5 Hz, H-3′), 4.67 (d, J 8 Hz, H-1′), 4.44 (d, 1 H, J 8 Hz, H-1), and 4.57–4.34 (3 H, inter alia H-1); ¹³C, δ 102.6, 101.8 (C-1 and C-1′), 99.6 (C-1″), and 30.0 (CH₂Br).

Anal. Calc. for C₃₄H₄₉BrO₂₃: C, 45.09; H, 5.45. Found: C, 45.22; H, 5.22.

2-Bromoethyl 2,3,6-tri-O-acetyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-Oacetyl-α-D-galactopyranosyl)-β-D-galactopyranosyl]-β-D-glucopyranoside (11). — (a) A solution of 10 (6.65 g, 7.3 mmol) in acetic anhydride–pyridine (1:1, 132 mL) was left at room temperature for 15 h and then co-concentrated with toluene. Crystallisation of the residue from ethanol gave 11 (5.22 g, 69%), m.p. 179–181°, $[\alpha]_{D}^{21}$ +45° (c 1.6, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.59 (bdd, 1 H, J~3 and <1 Hz, H-4″), 5.40 (dd, 1 H, J 11 and 3 Hz, H-3″), 5.22 (t, 1 H, J ~9 Hz, H-3), 5.18 (dd, 1 H, J 11 and 3.5 Hz, H-2″), 5.11 (dd, 1 H, J 11 and 8 Hz, H-2′), 4.99 (d, 1 H, J 3.5 Hz, H-1″), 4.92 (dd, 1 H, J 9.5 and 8 Hz, H-2), 4.74 (dd, 1 H, J 11 and 2.5 Hz, H-3′), 4.56 (d, 1 H, J 8 Hz, H-1), 4.53 (d, 1 H, J 8 Hz, H-1′), 4.02 (bd, 1 H, J ~2.5 Hz, H-4′), 3.65 (q, 1 H, J 9.5 and 2 Hz, H-5), and 3.46 (bt, 2 H, J~6 Hz, CH₂Br); ¹³C, δ 101.1 (d, J 165 Hz, C-1′), 100.7 (d, J 165 Hz, C-1), 99.6 (d, J 172 Hz, C-1″), and 29.9 (CH₂Br). Anal. Calc. for C₄₀H₅₅BrO₂₆: C, 46.56; H, 5.37. Found: C, 46.79; H, 5.39.

(b) Catalytic hydrogenation (1 atm., 10% Pd/C, 53 mg) of **12** (218 mg, 0.18 mmol) in acetic acid (12 mL) for 1.5 h, followed by filtration and removal of the solvent, gave a quantitative yield of 2-bromoethyl 2,3-di-O-benzoyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- β -D-galactopyranosyl]- β -D-glucopyranoside (**13**). Recrystallisation from methanol gave material with m.p. 218–220°, $[\alpha]_{D}^{21}$ +69° (c 0.7, chloroform). ¹H-N.m.r. data (CDCl₃, Me₄Si): δ 5.72 (t, 1 H, J 9.5 Hz, H-3), 5.59 (bd, 1 H, J \sim 3 Hz, H-4"), 5.35 (dd, 1 H, J 9.5 and 8 Hz, H-2), 5.29 (dd, 1 H, J 11 and 3 Hz, H-3"), 5.12 (dd, 1 H, J 11 and 8 Hz, H-2'), 4.98 (dd, 1 H, J 11 and 3.5 Hz, H-2"), 4.87 (d, 1 H, J 3.5 Hz, H-1"), 4.80 (d, 1 H, J 8 Hz, H-1), 4.66 (dd, 1 H, J 11 and 3 Hz, H-3'), 4.66 (d, 1 H, J 8 Hz, H-1'), 4.45 (bt, J \sim 6.5 Hz, H-5"), and 3.39 (t, 2 H, J 6.5 Hz, CH₂Br).

Anal. Calc. for C₄₈H₅₇BrO₂₅: C, 51.76; H, 5.16. Found: C, 51.93; H, 5.14.

Deacetylation of 13 with methanolic 0.02M sodium methoxide (20 mL) for 24 h, followed by neutralisation with Duolite C-26 (H⁺) resin and concentration, gave a residue that was acetylated (acetic anhydride-pyridine, 1:1, 50 mL) at room temperature for 22 h. Co-concentration with toluene then gave a residue that was subjected to column (1 \times 14 cm) chromatography (SiO₂; ethyl acetate-iso-octane, 2:1) to give 11 (80 mg, 43% from 12).

2-Bromoethyl 2,3-di-O-benzoyl-6-O-benzyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- α - and - β -D-galactopyranosyl]- β -Dglucopyranoside (14 and 12). — A solution of 1⁷ (2.7 g, 4 mmol) in dichloromethane (10 mL) at -78° was added to a solution of 8 (5.85 g, 10 mmol), silver trifluoromethanesulfonate (3.08 g, 12 mmol), and tetramethylurea (14.0 g, 12 mmol) in dichloromethane (15 mL). The mixture was treated as for the preparation of 9. Chromatography (SiO₂; ethyl acetate-iso-octane, 2:1) gave 14 (1.59 g, 34%) and a later fraction containing 12 (0.52 g, 11%).

Compound 14 was amorphous and had $[\alpha]_D^{21} + 122^\circ$ (*c* 1.3, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.73 (t, 1 H, *J* 9 Hz, H-3), 5.51 (bd, 1 H, *J* ~2.5 Hz, H-4"), 5.19 (dd, 1 H, *J* 11 and 3.5 Hz, H-2"), 5.16 (dd, 1 H, *J* 11 and 3.5 Hz, H-2'), 5.02 (dd, 1 H, *J* 11 and 2.5 Hz, H-3'), 4.90 (d, 1 H, *J* 3.5 Hz, H-1"), 4.79 (d, 1 H, *J* 8 Hz, H-1), 4.74, 4.62 (ABq, 2 H, *J*_{AB} 12.5 Hz, PhCH₂), and 3.42 (bt, 2 H, *J* 7 Hz, CH₂Br); ¹³C, δ 100.8 (d, *J* 164 Hz, C-1), 99.5 (d, *J* 172 Hz, C-1"), 97.0 (d, *J* 175 Hz, C-1"), and 29.6 (CH₂Br).

Compound 12 had m.p. 189–192° (from ethanol), $[\alpha]_{21}^{21}$ +65° (*c* 0.5, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.65 (t, 1 H, *J* 9.5 Hz, H-3), 5.58 (bd, 1 H, *J* 3 Hz, H-4″), 5.41 (dd, 1 H, *J* 9.5 and 8 Hz, H-2), 5.24 (dd, 1 H, *J* 11 and 3 Hz, H-3″), 5.06 (dd, 1 H, *J* 11 and 3.5 Hz, H-2″), 5.04 (dd, 1 H, *J* 11 and 8 Hz, H-2′), 4.85 (d, *J* 3.5 Hz, H-1″), 4.78, 4.56 (ABq, 2 H, *J*_{AB} 12 Hz, PhCH₂), 4.73 (d, 1 H, *J* 8 Hz, H-1), 4.52 (dd, 1 H, *J* 11 and 2.5 Hz, H-3′), 4.49 (d, 1 H, *J* 8 Hz, H-1′), 4.41 (bt, 1 H, *J* 7 Hz, H-5″), and 3.41 (bt, 2 H, *J* 7 Hz, CH₂Br); ¹³C, δ 101.2, 100.7 (2 d, *J* 161 and 160 Hz, C-1 and C-1′), 99.4 (d, *J* 172 Hz, C-1″), and 29.6 (CH₂Br). *Anal.* Calc. for C₅₅H₆₃BrO₂₅: C, 54.86; H, 5.27. Found: C, 54.84; H, 5.28.

2-(2-Methoxycarbonylethylthio)ethyl 2,3,6-tri-O-acetyl-4-O-[2,3,6-tri-Oacetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- β -D-galactopyranosyl]- β -D-glucopyranoside (15). — A mixture of 11 (3.09 g, 3 mmol), methyl 3-mercaptopropionate¹² (0.72 g, 6 mmol), cesium carbonate (1.2 g, 3.7 mmol), and N, N-dimethylformamide (15 mL) was stirred at room temperature for 1.5 h, and then partitioned between dichloromethane (100 mL) and water (25 mL). The organic phase was washed with water (20 mL), dried (Na₂SO₄), and concentrated. Chromatography (SiO₂; ethyl acetate-iso-octane, 2:1) gave 15 (2.81 g, 87%) as an amorphous solid, $[\alpha]_{D}^{21} + 36^{\circ}$ (c 1.1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.59 (dd, 1 H, J 3 and 1 Hz, H-4"), 5.40 (dd, 1 H, J 11 and 3 Hz, H-3"), 5.21 (t, 1 H, J 9 Hz, H-3), 5.18 (dd, 1 H, J 11 and 3.5 Hz, H-2"), 5.11 (dd, 1 H, J 11 and 8 Hz, H-2'), 4.99 (d, 1 H, J 3.5 Hz, H-1"), 4.90 (dd, 1 H, J 9.5 and 8 Hz, H-2), 4.73 (dd, 1 H, J 11 and 2.5 Hz. H-3'), 4.53 (d, 2 H, J 8 Hz, H-1 and H-1'), 3.71 (s, 3 H, MeO), 2.81 and 2.62 (2 bt, each 2 H, J ~7 Hz, SCH₂CH₂CO), and 2.71 (t, 2 H, J 7 Hz, CH₂S); ¹³C, δ 100.9, 100.4 (2 d, J 164 Hz, C-1 and C-1'), 99.4 (d, J 174 Hz, C-1"), and 51.6 (MeO).

2-(2-Methoxycarbonylethylthio)ethyl 4-O-(4-O-α-D-galactopyranosyl-β-Dgalactopyranosyl)-β-D-glucopyranoside (16). — A solution of 15 (1.07 g, 1 mmol) in methanolic 3mM sodium methoxide (40 mL) was left at room temperature for 42 h. The reaction was monitored by t.l.c. (SiO₂; chloroform-methanol-water, 65:35:10, lower phase). Crystalline 16 (412 mg) was then collected, washed with methanol, and dried. The filtrate was neutralised with Duolite C-26 (H⁺) resin, and concentrated; the residue crystallised from methanol to give a second crop of 16 (182 mg; total yield, 594 mg, 97%) as needles, m.p. 115–118°, $[\alpha]_{D}^{21}$ +54° (*c* 0.8, water). N.m.r. data: ¹H (Me₂SO-*d*₆, 50°, D₂O added, Me₄Si), δ 4.82, 4.29, 4.26 (3 d, each 1 H, *J* 3.5, 7, and 8 Hz, H-1″, H-1, H-1′), and 3.62 (s, 3 H, MeO); ¹³C (D₂O, TSP), δ 178.0, 106.0, 104.8 (2 d, *J* 163 and 160 Hz, C-1, C-1′), 103.0 (d, *J* 170 Hz, C-1″), 81.3, 80.1, 78.2, 77.6, 77.1, 75.6, 74.9, 73.6, 73.5, 71.8, 71.7 (CH₂), 71.66, 71.3, 63.2 (CH₂), 63.1 (CH₂), 62.8 (CH₂), 55.0 (MeO), 36.9 (CH₂), 33.5 (CH₂), and 29.2 (CH₂).

Anal. Calc. for C₂₄H₄₂O₁₈S: C, 44.30; H, 6.50. Found: C, 43.41; H, 6.71.

2-(Octadecylthio)ethyl 2,3,6-tri-O-acetyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- β -D-galactopyranosyl]- β -D-glucopyranoside (17). — A mixture of 11 (650 mg, 0.63 mmol), octadecanethiol (360 mg, 1.26 mmol), cesium carbonate (250 mg, 0.77 mmol), and *N*,*N*-dimethylformamide (3 mL) was stirred at room temperature for 78 h. The reaction was monitored by t.l.c. (SiO₂; ethyl acetate-iso-octane, 3:1). The mixture was diluted with dichloromethane (50 mL), washed with water (2 ×25 mL), dried (Na₂SO₄), and concentrated. Column (5 × 18 cm) chromatography (SiO₂; toluene and toluene–ethyl acetate, 1:1) gave amorphous 17 (677 mg, 87%), [α]²¹_D +33° (*c* 1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.59 (dd, 1 H, *J* 3 and 1 Hz, H-4"), 5.40 (dd, 1 H, *J* 11 and 3 Hz, H-3"), 5.22 (t, *J* 9 Hz, H-3), 5.18 (dd, 1 H, *J* 11 and 3.5 Hz, H-2"), 5.11 (dd, 1 H, *J* 11 and 8 Hz, H-2'), 4.99 (d, 1 H, *J* 3.5 Hz, H-1"), 4.90 (dd, 1 H, J 9.5 and 8 Hz, H-2), 4.73 (dd, 1 H, J 11 and 2.5 Hz, H-3'), 4.52 (d, 2 H, J 8 Hz, H-1 and H-1'), 4.58–4.39 (5 H, *inter alia* H-1 and H-1'), 2.68, 2.51 (2 t, each 2 H, J 7 Hz, CH₂SCH₂), and 0.88 (t, 3 H, J 6.5 Hz, CH₃CH₂); ¹³C, δ 101.1, 100.6 (2 d, J 164 and 162 Hz, C-1, C-1'), 99.6 (d, J 175 Hz, C-1"), and 14.1 (CH₃).

2-(Octadecylthio)ethyl 4-O-(4-O-α-D-galactopyranosyl-β-D-galactopyranosyl)-β-D-glucopyranoside (18). — A solution of 17 (1.0 g, 0.81 mmol) in methanolic 3mM sodium methoxide (100 mL) was left at room temperature for 24 h, neutralised with Duolite C-26 (H⁺) resin, filtered, and concentrated, and a solution of the residue in water (300 mL) was lyophilised to give 18 (580 mg, 88%), $[\alpha]_D^{21}$ +42° (*c* 0.7, methyl sulfoxide). N.m.r. data: ¹H (Me₂SO-*d*₆, 50°, D₂O added, Me₄Si), δ 4.81 (d, 1 H, *J* 3.5 Hz, H-1″), 4.27, 4.24 (2 d, each 1 H, *J* 7 and 8 Hz, H-1 and H-1′), 2.67, 2.52 (2 t, each 2 H, *J* 7.5 Hz, CH₂SCH₂), and 0.86 (t, 3 H, *J* 6.5 Hz, Me); ¹³C (CDCl₃-CD₃OD, 1:5), δ 105.2, 104.1 (2 d, *J* 162 Hz, C-1, C-1′), 102.6 (d, *J* 172 Hz, C-1″), 81.1, 80.0, 76.3 (3 C), 74.6 (2 C), 72.9, 72.5, 71.1, 70.9, 70.4, 70.3 (CH₂), 62.7 (CH₂), 62.0 (CH₂), 61.3 (CH₂), 33.2-29.7 (CH₂), 23.5 (CH₂), and 14.4 (CH₃).

Ethvl 2,3,6-tri-O-acetyl-4-O-[2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl)- β -D-galactopyranosyl]- β -D-glucopyranoside (19). — A solution of 11 (0.52 g, 0.5 mmol) in methanolic 7mM sodium methoxide (40 mL) was left at room temperature for 2 h and sodium hydroxide (95 mg) in water (2 mL) was then added. The mixture was hydrogenated (1 atm., Pd/C, 10%, 100 mg) for 100 min, filtered, neutralised with M hydrochloric acid, and concentrated. The residue was treated with acetic anhydride-pyridine (1:1, 100 mL) for 17 h at room temperature and the mixture was then co-concentrated with toluene. The residue was partitioned between dichloromethane (100 mL) and water (25 mL), and the organic phase was dried (Na₂SO₄) and concentrated. Column (5×18 cm) chromatography (SiO₂; ethyl acetate-iso-octane, 2:1) gave amorphous 19 (300 mg, 62%), $[\alpha]_{D}^{21}$ +41° (c 1, chloroform). N.m.r. data (CDCl₃, Me₄Si): ¹H, δ 5.91 (d, 1 H, J 3 Hz, H-4"), 5.40 (dd, 1 H, J 11 and 3 Hz, H-3"), 5.21 (t, 1 H, J 9 Hz, H-3), 5.18 (dd, 1 H, J 11 and 3.5 Hz, H-2"), 5.11 (dd, 1 H, J 11 and 8 Hz, H-2'), 4.99 (d, 1 H, J 3.5 Hz, H-1"), 4.88 (dd, 1 H, J 9 and 8 Hz, H-2), 4.73 (dd, 1 H, J 11 and 2.5 Hz, H-3'), 4.56-4.38 (5 H, inter alia H-1 and H-1'), 4.02 (d, 1 H, J 2.5 Hz, H-4'), and 1.19 (t, 3 H, J 7 Hz, CH₃CH₂); ¹³C, δ 100.9, 100.1 (2 d, J 160 and 164 Hz, C-1, C-1'), 99.4 (d, J 172 Hz, C-1"), and 14.9.

Ethyl 4-O-(4-O-α-D-galactopyranosyl-β-D-galactopyranosyl)-β-D-glucopyranoside (20). — A solution of 19 (440 mg, 0.46 mmol) in methanolic 5mM sodium methoxide (40 mL) was left at room temperature for 18 h, neutralised with Duolite C-26 (H⁺) resin, and concentrated, and a solution of the residue in water was lyophilised to give 20 (245 mg, 100%), $[\alpha]_D^{21}$ +71° (*c* 0.5, water). N.m.r. data: ¹H (Me₂SO-d₆, 50°, D₂O added, Me₄Si), δ 4.81 (d, 1 H, J 3.5 Hz, H-1″), 4.28, 4.20 (d, each 1 H, J 7 and 8 Hz, H-1 and H-1′), and 1.14 (t, 3 H, J 7 Hz, CH₃CH₂); ¹³C (D₂O, TSP), δ 106.1, 104.5, 103.2 (C-1,1′,1″), 81.5, 80.2, 78.3, 77.7, 77.3, 75.8, 75.0, 73.7, 73.6, 72.0, 71.8, 71.4, 69.1 (CH₂), 63.3 (CH₂), 63.2 (CH₂), 62.9 (CH₂), and 17.1. The results of sugar¹⁵ and methylation¹⁶ analysis were in agreement with the proposed structure.

Glycoprotein synthesis (cf. ref. 1). — (a) A solution of 16 (44 mg, 0.07 mmol) and hydrazine hydrate (85%, 0.25 mL) in ethanol (2 mL) was left overnight and then concentrated, and a solution of the residue in water was lyophilised. The resulting hydrazide was dissolved in methyl sulfoxide (1 mL), and then 4M hydrogen chloride in 1,4-dioxane (105 μ L) and a solution of *tert*-butyl nitrite (18 μ L, 0.15 mmol) in methyl sulfoxide (0.1 mL) were added. The mixture was stirred at room temperature for 30 min and a solution of sulfamic acid (10 mg, 0.11 mmol) in methyl sulfoxide (0.1 mL) was added. After 15 min, the mixture was added dropwise, with stirring, to a solution of bovine serum albumin (BSA; 65 mg, 1μ mol) in sodium tetraborate-potassium hydrogencarbonate buffer (2.5 mL, 0.08M Na₂ B_4O_7 and 0.35M KHCO₃). The pH was maintained at 9.0-9.3 by additions of M sodium hydroxide. The mixture was stirred for 16 h at room temperature, and then dialysed (H_2O , 72 h) and lyophilised to give glycoprotein 21. The degree of binding (number of hapten molecules per molecule of protein) was 14, as determined by the phenol-sulfuric acid method¹⁸. With 0.35 mmol of 16 and 1 μ mol of BSA, the degree of binding was 43.

(b) The procedure in (a) was followed, using 16 (114 mg, 0.18 mmol) and key-hole limpet haemocyanin (KLH, 30 mg, 0.034 μ mol), to give glycoprotein 22 with a degree of binding of 480.

2,3,6-Tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-[6,6-²H₂]galactopyranosyl)- α -D-[6,6-²H₂]galactopyranosyl bromide (23). — Compound 23 was prepared from 1,2,3,6-tetra-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-[6,6-²H₂]galactopyranosyl)- α -D-[6,6-²H₂]galactopyranose {m.p. 153–155°, $[\alpha]_D^{21}$ +138° (c 0.9, chloroform), prepared from "digalacturonic acid" as described⁵ for the protio compound except for the use of sodium borodeuteride in the reduction step; n.m.r. data were as expected} as described for 1, and used directly in the next step.

2-Bromoethyl 2,3,6-tri-O-benzyl-4-O-{2,3,6-tri-O-acetyl-4-O-{2,3,4,6-tetra-O-acetyl- α -D-[6,6-²H₂]galactopyranosyl)- β -D-[6,6-²H₂]galactopyranosyl}- β -D-glu-copyranoside (24). — Compound 24, prepared from 23 and 6 as described for 9, had m.p. 155–157°, $[\alpha]_{D}^{21}$ +58° (c 0.7, chloroform). The n.m.r. data were as expected.

2-Bromoethyl 4-O-{2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl- α -D-[6,6-²H₂]galactopyranosyl)- β -D-[6,6-²H₂]galactopyranosyl}- β -D-glucopyranoside (25). — Compound 25, prepared from 24 as described for 10, had m.p. 177–179°, $[\alpha]_{D}^{21}$ +78° (c 0.5, chloroform). The n.m.r. data were as expected.

2-Bromoethyl 2,3,6-tri-O-acetyl-4-O-{2,3,6-tri-O-acetyl-4-O-{2,3,4,6-tetra-O-acetyl- α -D-[6,6-²H₂]galactopyranosyl)- β -D-[6,6-²H₂]galactopyranosyl}- β -D-glu-copyranoside (26). — Compound 26, prepared from 25 as described for 11, had m.p. 181–183°, $[\alpha]_{\rm D}^{21}$ +44° (c 0.9, chloroform). The n.m.r. data were as expected.

ACKNOWLEDGMENTS

We thank Dr. F. Lindh (University of Lund) for sugar and methylation analyses, and Mr. G. Grönberg, Mr. T. Lave, and Ms. M. Levin for technical assistance.

REFERENCES

- 1 J. DAHMÉN, T. FREJD, G. MAGNUSSON, G. NOORI, AND A.-S. CARLSTROM, *Carbohydr. Res.*, 125 (1984) 237–245.
- 2 R. R. RACE AND R. SANGER, Blood Groups in Man, 6th edn., Blackwell, Oxford, 1975; M. NAIKI AND M. KATO, Vox Sang., 37 (1979) 30-38.
- 3 G. KALLENIUS, R. MOLLBY, S. B. SVENSON, J. WINBERG, A. LUNDBLAD, S. SVENSON, AND B. CEDERGREN, *FEMS Lett.*, 7 (1980) 297-302; H. LEFFLER AND C. SVANBORG-EDÉN, *ibid.*, 8 (1980) 127-134.
- 4 E. NUDELMAN, R. KANNAGI, S. HAKOMORI, M. PARSONS, M. LIPINSKI, J. WIELS, M. FELLOUS, AND T. TURSZ, *Science*, 220 (1983) 509–511.
- 5 J. DAHMÉN, T. FREID, T. LAVE, F. LINDH, G. MAGNUSSON, G. NOORI, AND K. PÅLSSON, Carbohydr. Res., 113 (1983) 219-224.
- 6 J. DAHMÉN, T. FREJD, G. MAGNUSSON, AND G. NOORI, Carbohydr. Res., 111 (1982) C1-C4.
- 7 J. DAHMÉN, T. FREJD, G. GRONBERG, T. LAVE, G. MAGNUSSON, AND G. NOORI, Carbohydr. Res., 116 (1983) 303-307.
- 8 J. DAHMÉN, T. FREID, G. GRONBERG, T. LAVE, G. MAGNUSSON, AND G. NOORI, *Carbohydr. Res.*, 118 (1983) 292–301.
- 9 D. D. COX, E. K. METZNER, AND E. J. REIST, Carbohydr. Res., 63 (1978) 139–147; P. J. GAREGG AND H. HULTBERG, *ibid.*, 110 (1982) 261–266.
- 10 D. M. HALL, Carbohydr. Res., 86 (1980) 158-160.
- 11 P. GAREGG AND H. HULTBERG, Carbohydr. Res., 93 (1981) c10-c11.
- 12 B. R. BAKER, M. V. QUERRY, S. BERNSTEIN, S. R. SAFIR, AND Y. SUBBAROW, J. Org. Chem., 12 (1947) 167–173.
- 13 J. K. INMAN, B. MERCHANT, L. CLAFLIN, AND S. E. TACEY, Immunochemistry, 10 (1973) 165-174.
- 14 R. U. LEMIEUX, D. R. BUNDLE, AND D. A. BAKER, J. Am. Chem. Soc., 97 (1975) 4076-4083.
- 15 J. S. SAWARDEKER, J. H. SLONEKER, AND A. JEANES, Anal. Chem., 37 (1965) 1602-1604.
- 16 H. BJORNDAL, C. G. HELLERQVIST, B. LINDBERG, AND S. SVENSSON, Angew. Chem., Int. Ed. Engl., 9 (1970) 610-619.
- 17 R. U. LEMIEUX AND J. D. STEVENS, Can. J. Chem., 43 (1965) 2059–2070; J. DAHMÉN, T. FREJD, G. GRONBERG, G. MAGNUSSON, AND G. NOORI, Carbohydr. Res., 125 (1984) 161–164.
- 18 M. DUBOIS, K. A. GILLES, J. K. HAMILTON, P. A. REBERS, AND F. SMITH, Anal. Chem., 28 (1956) 350–356.